202. Mansouri A, Taslimi S, Badhiwala JH, Witiw CD, Nassiri F, Odekerken VJJ, De Bie RMA, Kalia SK, Hodaie M, Munhoz RP, Fasano A, Lozano AM. Deep brain stimulation for Parkinson's disease: meta-analysis of results of randomized trials at varying lengths of follow-up. J Neurosurg. 2018 Apr;128(4):1199-1213. doi: 10.3171/2016.11.JNS16715. Epub 2017 Jun 30. PMID: 28665252.
203. Tan ZG, Zhou Q, Huang T, Jiang Y. Efficacies of globus pallidus stimulation and subthalamic nucleus stimulation for advanced Parkinson's disease: a meta-analysis of randomized controlled trials. Clin Interv Aging. 2016 Jun 21;11:777-86. doi: 10.2147/CIA.S105505. PMID: 27382262; PMCID: PMC4922790.
204. Xie CL, Shao B, Chen J, Zhou Y, Lin SY, Wang WW. Effects of neurostimulation for advanced Parkinson's disease patients on motor symptoms: A multiple- treatments meta-analysas of randomized controlled trials. Sci Rep. 2016 May 4;6:25285. doi: 10.1038/srep25285. PMID: 27142183; PMCID: PMC4855136.
205. Xu H, Zheng F, Krischek B, Ding W, Xiong C, Wang X, Niu C. Subthalamic nucleus and globus pallidus internus stimulation for the treatment of Parkinson's disease: A systematic review. J Int Med Res. 2017 Oct;45(5):1602-1612. doi: 10.1177/0300060517708102. Epub 2017 Jul 12. PMID: 28701061; PMCID: PMC5718722.
206. Tambasco N., Romoli M., Calabresi P. Levodopa in Parkinson’s disease: current status and future developments. Current neuropharmacology. 2018; 16(8):1239-1252.
207. Cristina S, Zangaglia R, Mancini F, Martignoni E, Nappi G, Pacchetti C. High- dose ropinirole in advanced Parkinson's disease with severe dyskinesias. Clin Neuropharmacol. 2003 May-Jun;26(3):146-50. doi: 10.1097/00002826-200305000-00008. PMID: 12782917.
208. Giménez-Roldán S, Esteban EM, Mateo D. Switching from bromocriptine to ropinirole in patients with advanced Parkinson's disease: open label pilot responses to three different dose-ratios. Clin Neuropharmacol. 2001 Nov-Dec;24(6):346-51. doi: 10.1097/00002826-200111000-00006. PMID: 11801810.
209. Pajo AT, Espiritu AI, Jamora RDG. Efficacy and safety of extended-release amantadine in levodopa-induced dyskinesias: a meta-analysis. Neurodegener Dis Manag. 2019 Aug;9(4):205-215. doi: 10.2217/nmt-2019-0011. Epub 2019 Aug 8. PMID: 31392922.
210. Elahi B, Phielipp N, Chen R. N-Methyl-D-Aspartate antagonists in levodopa induced dyskinesia: a meta-analysis. Can J Neurol Sci. 2012 Jul;39(4):465-72. doi: 10.1017/s0317167100013974. PMID: 22728853.
211. Sawada H, Oeda T, Kuno S, et al. Amantadine for dyskinesias in Parkinson’s disease: a randomized controlled trial. PloS ONE 2010;5:e15298.
212. Ory-Magne F, Corvol JC, Azulay JP, et al. Withdrawing amantadine in dyskinetic patients with Parkinson disease: the AMAN- DYSK trial. Neurology 2014;82:300-307
213. da Silva-Júnior FP, Braga-Neto P, Sueli Monte F, de Bruin VM. Amantadine reduces the duration of levodopa-induced dyskinesia: a randomized, double-blind, placebo- controlled study. Parkinsonism Relat Disord. 2005 Nov;11(7):449-52. doi: 10.1016/j.parkreldis.2005.05.008. Epub 2005 Sep 9. PMID: 16154788.
214. Stathis P, Konitsiotis S, Tagaris G, Peterson D. Levetiracetam for the management of levodopa-induced dyskinesias in Parkinson’s disease. Mov Disord 2011;26:264-270.
215. Durif F, Debilly B, Galitzky M, Morand D, Viallet F, Borg M, Thobois S, Broussolle E, Rascol O. Clozapine improves dyskinesias in Parkinson disease: a double-blind, placebo-controlled study. Neurology. 2004 Feb 10;62(3):381-8. doi: 10.1212/01.wnl.0000110317.52453.6c. PMID: 14872017.
216. Pierelli F, Adipietro A, Soldati G, Fattapposta F, Pozzessere G, Scoppetta C. Low dosage clozapine effects on L-dopa induced dyskinesias in parkinsonian patients. Acta Neurol Scand. 1998 May;97(5):295-9. doi: 10.1111/j.1600-0404.1998.tb05955.x. PMID: 9613557.
217. Gomide L, Kummer A, Cardoso F, Teixeira AL. Use of clozapine in Brazilian patients with Parkinson's disease. Arq Neuropsiquiatr. 2008 Sep;66(3B):611-4. doi: 10.1590/s0004-282x2008000500001. PMID: 18949249.
218. de Germay S, Montastruc F, Carvajal A, Lapeyre-Mestre M, Montastruc JL. Drug-induced parkinsonism: Revisiting the epidemiology using the WHO pharmacovigilance database. Parkinsonism Relat Disord. 2020 Jan;70:55-59. doi: 10.1016/j.parkreldis.2019.12.011. Epub 2019 Dec 17. PMID: 31865063.
219. Mansouri A, Taslimi S, Badhiwala JH, Witiw CD, Nassiri F, Odekerken VJJ, De Bie RMA, Kalia SK, Hodaie M, Munhoz RP, Fasano A, Lozano AM. Deep brain stimulation for Parkinson's disease: meta-analysis of results of randomized trials at varying lengths of follow-up. J Neurosurg. 2018 Apr;128(4):1199-1213. doi: 10.3171/2016.11.JNS16715. Epub 2017 Jun 30. PMID: 28665252.
220. Tan ZG, Zhou Q, Huang T, Jiang Y. Efficacies of globus pallidus stimulation and subthalamic nucleus stimulation for advanced Parkinson's disease: a meta-analysis of randomized controlled trials. Clin Interv Aging. 2016 Jun 21;11:777-86. doi: 10.2147/CIA.S105505. PMID: 27382262; PMCID: PMC4922790.
221. Xie CL, Shao B, Chen J, Zhou Y, Lin SY, Wang WW. Effects of neurostimulation for advanced Parkinson's disease patients on motor symptoms: A multiple- treatments meta-analysas of randomized controlled trials. Sci Rep. 2016 May 4;6:25285. doi: 10.1038/srep25285. PMID: 27142183; PMCID: PMC4855136.
222. Xu H, Zheng F, Krischek B, Ding W, Xiong C, Wang X, Niu C. Subthalamic nucleus and globus pallidus internus stimulation for the treatment of Parkinson's disease: A systematic review. J Int Med Res. 2017 Oct;45(5):1602-1612. doi: 10.1177/0300060517708102. Epub 2017 Jul 12. PMID: 28701061; PMCID: PMC5718722.
223. DeMaagd G, Fhilip A. Parkinson’s disease and its management: part4: treatment of motor complications. Pharmacy and therapeutics. 2015; 40 (11) 747
224. Koay L, Rose J, Abdelhafiz AH. Factors that lead to hospitalisation in patients with Parkinson disease-A systematic review. Int J Clin Pract. 2018 Jan;72(1). doi: 10.1111/ijcp.13039. Epub 2017 Nov 9. PMID: 29119656
225. Simonet C, Tolosa E, Camara A, Valldeoriola F. Emergencies and critical issues in Parkinson's disease. Pract Neurol. 2020;20(1):15-25. doi:10.1136/practneurol-2018-002075